查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930146

全球前列腺癌疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Prostate Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 169 Pages | 商品交期: 请询问到货日

价格

前列腺癌疫苗市场成长因素

由于前列腺癌发病率的上升以及对基于免疫疗法的先进治疗方案需求的增加，全球前列腺癌疫苗市场正经历显着增长。前列腺癌疫苗是一种治疗性疫苗，旨在透过激活患者自身的免疫系统来识别和靶向癌细胞，从而减缓疾病进展并预防復发。 这些疫苗尚未获准用于预防，主要用于疾病晚期。

根据这份报告，全球前列腺癌疫苗市场预计到2025年将达到5.3亿美元。预计到2026年，市场规模将成长至5.8亿美元，到2034年将达到15.5亿美元，在预测期（2026-2034年）内复合年增长率（CAGR）为12.98%。北美在2025年占市场主导地位，市占率高达79.56%。这主要得益于该地区较高的疾病盛行率、完善的医疗基础设施以及免疫疗法的早期应用。

全球前列腺癌病例的不断增加持续推动着对新疗法的需求。传统的疗法，例如荷尔蒙疗法和化疗，其长期疗效往往较低，尤其是在去势抵抗性前列腺癌等晚期阶段，因此需要创新的疫苗疗法。

市场驱动因素

市场成长的主要驱动因素是荷尔蒙疗法（包括雄性激素剥夺疗法 (ADT)）抗药性的增加。 ADT 最初透过降低睪固酮水平来抑制肿瘤生长，但许多患者最终由于基因突变和适应性癌症路径而产生抗药性。这种抗药性降低了治疗效果并促进了疾病进展，从而催生了对替代疗法（例如前列腺癌疫苗）的需求。

此外，全球前列腺癌负担的加重扩大了符合条件的患者群体。临床医生和患者对免疫疗法优势（例如标靶性、低毒性和与联合疗法的兼容性）的认识不断提高，进一步推动了市场成长。

市场限制因子

限制市场扩张的主要因素之一是目前已获批准的疫苗 PROVENGE（sipoleucel-T）的给药过程冗长而复杂。 这种疗法需要进行白血球分离术、密集的细胞处理和回输，促使多个临床步骤，耗时数天。这一耗时的过程增加了物流复杂性、治疗成本和患者负担，阻碍了其广泛应用。

市场挑战

市场面临复杂的监管要求和较高的临床试验失败率等挑战。个人化癌症疫苗需要严格的处理、储存和运输条件以维持细胞完整性，这促使营运成本增加。此外，严格的监管审查往往会延迟审批。

临床试验失败也是一项重大挑战。多种在研疫苗未能证明其足够的疗效，促使经济损失和创新进程的延迟。这些因素共同作用，减缓了产品开发和市场渗透。

市场机会

由于已获批准的疫苗供应有限以及人们对免疫疗法研究的兴趣日益浓厚，前列腺癌疫苗市场展现出强劲的增长机会。 未被满足的需求正推动製药和生技公司投资研发新的候选疫苗，特别是针对早期和局部前列腺癌的疫苗。

后期临床试验的正面结果和研发投入的增加正在扩大研发管线。预计新型病毒免疫疗法和联合治疗策略将在预测期内开闢新的成长途径。

市场趋势

影响市场的关键趋势是基于DNA的前列腺癌疫苗的进步。这些疫苗利用肿瘤特异性抗原和肿瘤相关抗原来刺激强烈的细胞免疫反应。 DNA疫苗平台能够实现多抗原靶向，从而提高免疫活化和治疗效果。

对个人化医疗和联合免疫疗法的日益关注正在推动进一步的创新。将基于DNA的疫苗与免疫检查点抑制剂和荷尔蒙疗法相结合正在临床研究中受到越来越多的关注。

市场区隔分析

依产品划分，市场分为 PROVENGE（Sipulesel-T）及其他产品。 PROVENGE 产品占市场主导地位，因为它是唯一获得 FDA 批准的前列腺癌疫苗，其临床疗效已得到证实，并且对个性化免疫疗法的需求日益增长。

依最终用户划分，市场分为医院、专科诊所和其他机构。医院凭藉其先进的基础设施、技术精湛的专业人员以及进行复杂免疫疗法的能力，占最大的市场占有率。由于标靶肿瘤服务的扩展，专科诊所预计将保持稳定成长。

区域展望

预计北美将引领摄护腺癌疫苗市场，2025年市场规模将达4.2亿美元，2026年将成长至4.6亿美元。该地区受益于摄护腺癌高发生率、有利的医疗保险政策以及输液中心的广泛应用。欧洲将占第二大市场占有率，这主要得益于公众意识的提高和早期诊断措施的进展。亚太地区预计将以显着的复合年增长率成长，这主要得益于疾病盛行率的上升和癌症治疗设施的扩建。同时，拉丁美洲以及中东和非洲地区的成长速度将较为缓慢，这主要是由于治疗费用高昂和公众意识不足。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区的摄护腺癌盛行率（2025 年）
  • 主要公司的产品线分析
  • 市场技术进步
  • 主要公司的新产品发布
  • 关键产业趋势：併购、业务合作等

第五章 全球前列腺癌疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品分类
    • PROVENGE（Sipoleucel-T）
    • 其他
  • 市场分析、洞察与预测：依最终用户分类
    • 医院
    • 专科诊所
    • 其他
  • 市场分析、洞察与预测：依地区分类
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美前列腺癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家分类
    • 美国州/省
    • 加拿大

第七章 欧洲前列腺癌疫苗市场分析：洞察与预测（2021-2034）

  • 各国
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲各国

第八章 亚太地区前列腺癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 其他亚太地区国家

第九章 拉丁美洲前列腺癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲前列腺癌疫苗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 其他中东和非洲国家

第十一章：竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • Dendreon Pharmaceuticals LLC.
    • Barinthus Biotherapeutics
    • Candel Therapeutics, Inc.
    • BioNTech
    • Madison Vaccines, Inc.
Product Code: FBI113610

Growth Factors of prostate cancer vaccines Market

The global prostate cancer vaccines market is witnessing notable growth, driven by the rising prevalence of prostate cancer and increasing demand for advanced immunotherapy-based treatment options. Prostate cancer vaccines are therapeutic vaccines designed to activate the patient's immune system to recognize and target cancer cells, thereby delaying disease progression or controlling recurrent disease. These vaccines are not approved for preventive use and are primarily utilized in advanced disease stages.

According to the report, the global prostate cancer vaccines market was valued at USD 0.53 billion in 2025. The market is projected to grow to USD 0.58 billion in 2026 and further reach USD 1.55 billion by 2034, registering a CAGR of 12.98% during the forecast period (2026-2034). North America dominated the market in 2025, accounting for a 79.56% market share, supported by high disease prevalence, strong healthcare infrastructure, and early adoption of immunotherapy.

The growing number of prostate cancer cases worldwide continues to fuel demand for novel treatment approaches. Conventional therapies such as hormone therapy and chemotherapy often show reduced long-term effectiveness, particularly in advanced stages such as castration-resistant prostate cancer, thereby increasing the need for innovative vaccine-based therapies.

Market Drivers

A key driver of market growth is the increasing resistance to hormonal therapies, including androgen deprivation therapy (ADT). While ADT initially reduces tumor growth by lowering testosterone levels, many patients eventually develop resistance due to genetic mutations and adaptive cancer pathways. This resistance reduces treatment efficacy and increases disease progression, creating demand for alternative therapies such as prostate cancer vaccines.

Additionally, the growing global burden of prostate cancer is expanding the eligible patient population. Rising awareness among clinicians and patients regarding immunotherapy benefits-such as targeted action, lower toxicity, and compatibility with combination therapies-further supports market growth.

Market Restraints

One of the major restraints limiting market expansion is the lengthy and complex administration process of the currently approved vaccine, PROVENGE (Sipuleucel-T). The therapy requires leukapheresis, centralized cell processing, and reinfusion, spanning several days and multiple clinical steps. This time-intensive process increases logistical complexity, treatment costs, and patient burden, thereby restricting wider adoption.

Market Challenges

The market faces challenges related to complex regulatory requirements and high clinical trial failure rates. Personalized cancer vaccines require stringent handling, storage, and transportation conditions to maintain cellular integrity, leading to higher operational costs. In addition, strict regulatory scrutiny often delays approvals.

Clinical trial failures also pose a significant challenge. Several investigational vaccines have failed to demonstrate sufficient efficacy, resulting in financial losses and delayed innovation. These factors collectively slow product development and market penetration.

Market Opportunities

The prostate cancer vaccines market presents strong growth opportunities due to the limited availability of approved vaccines and the rising interest in immunotherapy research. The unmet clinical need has encouraged pharmaceutical and biotechnology companies to invest in developing new vaccine candidates, particularly for early-stage and localized prostate cancer.

Positive outcomes from late-stage clinical trials and increasing R&D investments are expanding the development pipeline. Novel viral immunotherapies and combination treatment strategies are expected to create new growth avenues over the forecast period.

Market Trends

A significant trend shaping the market is the advancement of DNA-based prostate cancer vaccines. These vaccines use tumor-specific and tumor-associated antigens to stimulate strong cellular immune responses. DNA vaccine platforms allow for multi-antigen targeting, improving immune activation and therapeutic effectiveness.

Increasing focus on personalized medicine and combination immunotherapy approaches is further accelerating innovation. DNA-based vaccines combined with immune checkpoint inhibitors and hormone therapy are gaining traction in clinical research.

Segmentation Analysis

By product, the market is divided into PROVENGE (Sipuleucel-T) and others. The PROVENGE segment dominates the market due to its status as the only FDA-approved prostate cancer vaccine, established clinical efficacy, and rising preference for personalized immunotherapy.

Based on end user, the market is segmented into hospitals, specialty clinics, and others. Hospitals hold the largest market share, owing to their advanced infrastructure, skilled professionals, and ability to administer complex immunotherapy procedures. Specialty clinics are expected to grow steadily due to the expansion of targeted oncology services.

Regional Outlook

North America led the prostate cancer vaccines market in 2025, with a market value of USD 0.42 billion, increasing to USD 0.46 billion in 2026. The region benefits from high prostate cancer incidence, favorable reimbursement policies, and widespread availability of infusion centers. Europe holds the second-largest share due to rising awareness and early diagnostic initiatives. The Asia Pacific region is expected to grow at a significant CAGR, driven by increasing disease prevalence and expansion of cancer care facilities. Latin America and the Middle East & Africa show slower growth due to high treatment costs and limited awareness.

Competitive Landscape

The market is highly consolidated, with Dendreon Pharmaceuticals LLC. holding a dominant position due to PROVENGE. Other players such as Barinthus Biotherapeutics, Candel Therapeutics, BioNTech, and Madison Vaccines are actively engaged in clinical research and product development. Strategic investments, clinical trial advancements, and innovation in vaccine platforms are expected to shape the competitive landscape during the forecast period.

Conclusion

The prostate cancer vaccines market is poised for strong growth, driven by the rising global burden of prostate cancer and the increasing shift toward immunotherapy-based treatment approaches. Valued at USD 0.53 billion in 2025, the market is projected to grow to USD 0.58 billion in 2026 and further reach USD 1.55 billion by 2034, registering a robust CAGR of 12.98% during 2026-2034. The growing limitations of conventional hormone therapies, particularly in advanced and castration-resistant prostate cancer, continue to create demand for innovative vaccine-based solutions.

Despite challenges such as complex administration procedures, high treatment costs, and stringent regulatory requirements, ongoing advancements in DNA-based vaccines, personalized immunotherapy, and combination treatment strategies are expected to drive future market expansion. The strong dominance of North America, supported by early adoption of immunotherapy and favorable reimbursement policies, further strengthens the market outlook. Overall, continued R&D investments, expanding clinical pipelines, and rising awareness of therapeutic cancer vaccines are expected to support sustained growth of the prostate cancer vaccines market through 2034.

Segmentation By Product

  • PROVENGE (sipuleucel-T)
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America (By Product, End User, and Country )
    • U.S.
    • Canada
  • Europe (By Product, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Product, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Product, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Technological Advancements in Market
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. PROVENGE (sipoleucel-T)
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By End User
    • 5.2.1. Hospitals
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. PROVENGE (sipoleucel-T)
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By End User
    • 6.2.1. Hospitals
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. PROVENGE (sipoleucel-T)
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By End User
    • 7.2.1. Hospitals
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Rest of Europe

8. Asia Pacific Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. PROVENGE (sipoleucel-T)
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By End User
    • 8.2.1. Hospitals
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Rest of Asia Pacific

9. Latin America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. PROVENGE (sipoleucel-T)
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By End User
    • 9.2.1. Hospitals
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. PROVENGE (sipoleucel-T)
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By End User
    • 10.2.1. Hospitals
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Dendreon Pharmaceuticals LLC.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Barinthus Biotherapeutics
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc
    • 11.2.3. Candel Therapeutics, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc
    • 11.2.4. BioNTech
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc
    • 11.2.5. Madison Vaccines, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc

List of Tables

  • Table 1: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 2: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 3: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 4: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 5: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 6: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 7: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 8: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 9: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 11: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 12: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 14: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 15: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 17: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 18: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Prostate Cancer Vaccines Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Prostate Cancer Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Prostate Cancer Vaccines Market Value Share (%), by End User, 2025 & 2034
  • Figure 4: Global Prostate Cancer Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 5: North America Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 6: North America Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 7: North America Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 8: North America Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 9: North America Prostate Cancer Vaccines Market Value (USD million), By Country, 2025 & 2034
  • Figure 10: North America Prostate Cancer Vaccines Market Value Share (%), By Country, 2025
  • Figure 11: Europe Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 12: Europe Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 13: Europe Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 14: Europe Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 15: Europe Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 18: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 19: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 20: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 21: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 24: Latin America Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 25: Latin America Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 26: Latin America Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 27: Latin America Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 30: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 31: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 32: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 33: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Prostate Cancer Vaccines Market Share (%), By Company, 2025